Protagonist TherapeuticsPTGX
PTGX
About: Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Employees: 126
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
75% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 7 (+3) [Q4]
20% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 75
13% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 40
1.29% more ownership
Funds ownership: 104.83% [Q3] → 106.12% (+1.29%) [Q4]
0% more funds holding
Funds holding: 238 [Q3] → 239 (+1) [Q4]
8% less call options, than puts
Call options by funds: $8.73M | Put options by funds: $9.52M
12% less capital invested
Capital invested by funds: $2.78B [Q3] → $2.44B (-$337M) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
18%
downside
Avg. target
$64
38%
upside
High target
$80
73%
upside
8 analyst ratings
7 positive
88%
1 neutral
13%
0 negative
0%
HC Wainwright & Co. Douglas Tsao 17% 1-year accuracy 29 / 171 met price target | 73%upside $80 | Buy Reiterated | 10 Apr 2025 |
Wedbush Yun Zhong 0% 1-year accuracy 0 / 6 met price target | 51%upside $70 | Outperform Reiterated | 28 Mar 2025 |
Truist Securities Srikripa Devarakonda 16% 1-year accuracy 5 / 31 met price target | 64%upside $76 | Buy Maintained | 11 Mar 2025 |
BMO Capital Etzer Darout 15% 1-year accuracy 5 / 33 met price target | 56%upside $72 | Outperform Reiterated | 11 Mar 2025 |
Citizens Capital Markets Jonathan Wolleben 33% 1-year accuracy 23 / 69 met price target | 32%upside $61 | Market Outperform Reiterated | 10 Mar 2025 |
Financial journalist opinion
Neutral
Accesswire
3 days ago
Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that on April 15, 2025 (the "Grant Date"), it issued an equity inducement award to a new employee upon his commencement of employment with the Company in accordance with the terms of his employment offer letter. The award was granted under the Company's Amended and Restated 2018 Inducement Plan, which was adopted on May 29, 2018, and amended on February 18, 2020 and February 15, 2022.
Positive
Zacks Investment Research
3 weeks ago
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Accesswire
1 month ago
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others NEWARK, CA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced its inclusion in Fast Company's prestigious annual list of the World's Most Innovative Companies for 2025. Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and transformative technologies.
Positive
Zacks Investment Research
1 month ago
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Seeking Alpha
1 month ago
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It
Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotrokinra, a first-in-class IL-23 receptor agonist, shows promise in treating ulcerative colitis and plaque psoriasis, potentially shifting treatment paradigms in both of these indications. Financially stable with $559.2 million in cash and recent milestone payments, Protagonist can fund operations through 2028, reducing financial risk.
Positive
Zacks Investment Research
1 month ago
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
Positive
Schwab Network
1 month ago
Overlooked Stock: PTGX
Protagonist Therapeutics (PTGX) rallied 45% after its latest drug trial to treat people with active ulcerative colitis saw success. George Tsilis says there's more positive catalysts behind the stock, particularly its cash pile.
Positive
Investors Business Daily
1 month ago
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study. The post Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out appeared first on Investor's Business Daily.
Positive
Benzinga
1 month ago
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC).
Neutral
Business Wire
1 month ago
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first.
Charts implemented using Lightweight Charts™